Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Aspen Park Pharmaceuticals

Aspen Park Pharmaceuticals?uq=U5Zpp9ZJ
2014 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
3 FINANCING ROUNDS
Description

Developer of novel therapies for premature ejaculation in men. The company focuses on the development and commercialization of novel therapies for men's health diseases and conditions, including male secondary hypogonadism, prostate cancer, and sexual dysfunction.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Therapeutic Devices
Other Industries
Clinics/Outpatient Services
Managed Care
Acquirer
Primary Office
  • 944 Park Avenue
  • New York, NY 10028
  • United States

Aspen Park Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Aspen Park Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Aspen Park Pharmaceuticals Executive Team (2)

Name Title Board
Seat
Contact
Info
Harry Fisch Co-Founder, Chairman & Chief Scientific Officer
Mitchell Steiner Ph.D Co-Founder, President, Managing Director & Chief Executive Officer

Aspen Park Pharmaceuticals Board Members (2)

Name Representing Role Since Contact
Info
00000 000000000 Aspen Park Pharmaceuticals Board Member 000 0000
0000000 00000 Self Board Member 000 0000